Join us for the First Annual Boston Society Medical Symposium on Acute Myeloid Leukemia (AML)
March 15, 2018

Broad Institute of MIT and Harvard 
415 Main Street 
Cambridge, MA 02142

 

Download a copy of the conference program:

AML 2018 Program Guide

 

Plenary Speaker

 

Gwen Nichols, MD, Chief Medical Officer, The Leuklemia & Lymphoma Society

Can AML Precision Science Become AML Precision Clinical Reality?

     

 

Invited Speakers 

 

Naval G. Daver, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Immune Checkpoint and Vaccine Approaches in AML

 

 

Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

FDA Work to Expedite the Development of Products to Address Serious and Life-Threatening Conditions

             
 

Andrew M. Brunner MD, Center for Leukemia, Massachusetts General Hospital

State of the Clinic: Treating AML in 2018

     

Bikash Verma, MD, DVM, Head, Clinical Development & Medical Affairs, Celyad

Novel CAR-T Therapy for AML 

 

             
   

John F. DiPersio, MD, PhD, Virginia E and Samuel J Golman Professor, Chief, Division of Oncology, Deputy Director, Siteman Cancer Center, Washington University School of Medicine

Novel Targeting of AML and T-ALL

     

Patrick Zweidler-McKay, MD, PhD, Medical Director for Hematologic Malignancies, ImmunoGen

ADCs in AML: GO and Beyond

             
 

Terry J. Fry, MD, Investigator, Pediatric Oncology Branch, Head, Hematologic Malignancies Section, Center for Cancer Research, National Cancer Institute

Immunotherapeutic Approaches for AML

     

Yi-Bin Albert Chen, MD, Program Director, Blood & Marrow Transplant (BMT) Program at the MGH Cancer Center

AML after Transplant: Are We Becoming High Maintenance?

             
 

Coleman Lindsley, MD, PhD, Assistant Professor, Harvard Medical School, Dana-Farber Cancer Institute

genomics of myeloid malignancies -Title TBA

     

Karin Gaensler, MD, Clinical Professor of Medicine, UCSF

TriLeukeVax: A "Next Generation" Autologous Immunotherapy for Leukemia

             

 

AML 2018 Sessions 

Session I:  The Current Landscape

Session II:  State of the Art Research and Treatment Options

Session III:  On the Horizon

 

 

 

 

 Join our Linkedin Group:

Sessions

Session I:  The Current Landscape

Session II:  State of the Art Research and Treatment Options

Session III:  On the Horizon

Registration

Click here to register for the AML 2018 conference online.

AML 2018 will take place

March 15, 2018

Broad Institute

Cambridge, MA

 

The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3

Updates

Sign Up Today!

Privacy Policy